Eric Ostertag, M.D., Ph.D.

Chief Executive Officer

  • Founder and CEO of Transposagen and co-inventor of its technologies
  • Co-founder and CEO of PhenoTech and Vindico
  • M.D.-Ph.D., residency  and fellowship at UPenn
  • Scientific and clinical awards from American Society of Human Genetics, American Society for Apheresis
  • Howard Hughes Medical Institute Fellow
  • Over 12 years of executive management experience

Nishan de Silva, M.D. 

President and Chief Operating Officer

  • Over 16 years of healthcare experience across biotechnology operating roles, Board of Director positions, biotechnology investing, and healthcare management consulting
  • Former Vice President, Finance and Strategy and Chief Financial Officer at Ligand Pharmaceuticals, $2B+ market cap, profitable biotechnology company
  • Former Principal in Healthcare Group at Warburg Pincus LLC and member of Board of Directors of several public and private biotechnology companies
  • Former Engagement Manager at McKinsey & Company
  • M.D. from The University of Pennsylvania School of Medicine, M.B.A. from The Wharton School and B.A. in Biology from Harvard University

Matthew Spear, M.D.  

Chief Medical Officer

  • Over 20 years of research and development experience
  • Former Vice President Clinical Development at Incyte Corporation
  • Former Head of Oncology and Head of Biotherapeutics at Sunovion Pharmaceuticals
  • Former Chief Medical Officer and Senior Vice President at Nereus Pharmaceuticals
  • Served as an Associate Professor at USC Keck School of Medicine and the UCSD Medical School and Cancer Center
  • M.D. from Stanford University with post-graduate training at Massachusetts General Hospital/Harvard University program

Debra Gessner  

Vice President, Regulatory Affairs

  • Former Vice President Regulatory and Quality Affairs at Tocagen Inc. and Sirion Therapeutics
  • More than 25 years of hands-on regulatory and compliance experience
  • Previously served as Director of Regulatory Affairs and Quality Assurance at Bruin Pharma and Santarus Inc.
  • Member of the Regulatory Affairs Professional Society (RAPS), Parental Drug Association (PDA) and American Society for Gene Therapy
  • M.Sc. in Regulatory Affairs from San Diego State University and B.S. in Medical Technology from the University of Texas Medical Branch in Galveston
Devon Shedlock, Ph.D.

Vice President, Preclinical Development

  • Over 15 years of T cell immunology experience, including CAR-T cell immunotherapy, immuno-oncology and vaccine development
  • Previously served as Associate Director, T Cell Engineering Lab at Abramson Cancer Center
  • Former Adjunct Assistant Professor for the Department of Pathology and Laboratory Medicine at University of Pennsylvania Perelman School of Medicine
  • Ph.D. in Cell and Molecular Biology from the University of Pennsylvania School of Medicine
  • Authored over 35 peer-reviewed papers, reviews, and book chapters in the field of T cell immunology

Glenn Dourado 

Vice President, Business Development

  • Former Senior Director Business Development at Ligand Pharmaceuticals
  • Over 16 years of experience in biotechnology business development with proven track record, closing over 60 biotechnology licensing transactions
  • Previously worked at Sanford Burnham Medical Research Institute, Metabasis Therapeutics, The Dow Chemical Company, Agouron Pharmaceuticals and Johnson & Johnson
  • M.B.A. from Queen’s University, M.S. from the University of Calgary and B.S. from the University of Alberta